Dr. Mjalli is an internationally recognized expert in drug discovery and development of new medicines in the pharmaceutical and biotechnology industry.  Dr. Mjalli is the founder, Chairman of the Board, President & CEO of TransTech Pharma, Inc., a drug discovery and development company and currently serves as Chairman of the Board of PharmaCore a drug discovery tool company, having previously been its founder, President and CEO.  Dr. Mjalli obtained his Ph.D. in medicinal chemistry in 1989 from the University of Exeter, UK. His postdoctoral work was carried out at the University of Rochester. Dr. Mjalli has held various positions of increasing responsibility in research and senior management at several pharmaceutical and biotechnology companies including Merck & Co., Inc. and Ontogen Corporation. He is the author of more than 40 scientific papers, four book chapters and an inventor on more than 620 patents and patent applications. Dr. Mjalli also serves on the Board of Directors of Siga Technologies, the North Carolina Biotechnology Center, and High Point Economic Development Corporation.  Dr. Mjalli has raised more than $110M for TransTech Pharma and PharmaCore.

Dr. Mjalli has been the recipient of several awards and honors including: the 2007 “Fast 50 Award” honoring the Triad’s 50 fastest growing private companies and their CEOs, Carolinas regional “Finalist for Ernst & Young 2007 Entrepreneur of the Year”, the “Health Care Heroes Innovator Award”  and the “North Carolina Biotechnology Economic Development Award” from the North Carolina Biotechnology Center. He has been named among the “Triad’s Most Influential People”, was issued the “City of High Point North Carolina Key Award” and awarded the “Science Award in Recognition and Appreciation of Excellence in Innovation and Creativity” by Helios Pharmaceuticals.  As a student, he was the recipient of academic awards such as the Glaxo Group Research Scholarship for Ph.D. degree, the Lovis Rydon Memorial Research Prize for Outstanding Research from the University of Exeter and the European Economic Community Scholarship for M.S. degree.